New study: postpartum depression treatment may soon be available at home

NCT ID NCT05059600

Completed Symptom relief Sponsor: Supernus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether the drug ZULRESSO (brexanolone) can be safely given to women with postpartum depression in their own homes instead of a hospital. Fifty-two women took part. The main goal was to see if any side effects caused the infusion to be stopped or interrupted. The results help show whether home treatment is a safe option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Brexanolone (ZULRESSO), a synthetic version of the hormone allopregnanolone, given as an intravenous infusion
What this could lead to: If successful, this could allow women with postpartum depression to receive treatment in the comfort of their own home instead of a hospital.
What could go wrong: This is a small, completed phase 4 study focused on safety and feasibility, not on how well the drug works. Home administration may still carry risks like infusion reactions or need for medical backup.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTPARTUM DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postpartum depression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTPARTUM DEPRESSION

Contacts and locations

Locations

Sage Investigational Site

Culver City, California, 90230, United States
Sage Investigational Site

Miramar, Florida, 33029, United States
Sage Investigational Site

Pompano Beach, Florida, 33060, United States
Sage Investigational Site

New York, New York, 10036, United States
Sage Investigational Site

League City, Texas, 77573, United States
Virtual Site (recruiting nationwide)

Culver City, California, 90230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.